Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JDHD | ISIN: IL0011417206 | Ticker-Symbol: 4SG
Frankfurt
28.03.24
08:00 Uhr
0,865 Euro
-0,005
-0,57 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SOL-GEL TECHNOLOGIES LTD Chart 1 Jahr
5-Tage-Chart
SOL-GEL TECHNOLOGIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8600,93028.03.

Aktuelle News zur SOL-GEL TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.03.Korrosionsschutz: Verbesserte Korrosionsbeständigkeit und hydrophobe Stabilität von Sol-Gel-Beschichtungen1
14.03.Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M1
13.03.Sol-Gel Technologies: Q4 Earnings Insights1
13.03.Sol-Gel Technologies Ltd. - 20-F, Annual and transition report of foreign private issuers1
13.03.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
13.03.Sol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments277An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025...
► Artikel lesen
29.02.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
17.01.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
30.11.23Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer-
30.11.23Sol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study422SGT-610 has "Orphan Drug" designation status in the U.S. and E.U. and "Breakthrough Therapy" designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs...
► Artikel lesen
28.11.23Sol-Gel Technologies Ltd.: Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-6101
20.11.23Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
09.11.23Sol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48M1
09.11.23Recap: Sol-Gel Technologies Q3 Earnings1
09.11.23Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
09.11.23Sol-Gel Technologies Ltd.: Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update147Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains...
► Artikel lesen
10.08.23Sol-Gel Technologies Ltd.: Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update136Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel's recently announced agreement with Searchlight Pharma will provide...
► Artikel lesen
12.05.23Sol-Gel Technologies Ltd.: Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update425Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib)...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1